Literature DB >> 9441775

Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases.

M P Luo1, B Gomperts, S Imren, Y A DeClerck, M Ito, M Velicescu, J C Felix, L Dubeau.   

Abstract

OBJECTIVES: To obtain long-term cultures of ovarian cystadenomas and ovarian tumors of low malignant potential (LMP) displaying gene expression patterns similar to those found in vivo and test the hypothesis that such cultures would express different levels of matrix-degrading proteinases than cultured ovarian carcinomas.
METHODS: Transfection with an adenoviral expression vector for simian virus 40 (SV40) large T antigen was used to establish long-term cultures of the above tumors. Levels of expression of various genes were evaluated using molecular biological and immunohistochemical approaches. Zymography and reverse zymography were used to examine the activity of various metalloproteinases and plasminogen activators (PA). Two-sided P values for differences in plasminogen activator expression between different cell types were evaluated by Fisher's exact test.
RESULTS: Long-term cultures derived from cystadenomas and LMP tumors were obtained which formed colonies on semisolid supports, but were not tumorigenic in nude mice. The cultured cells expressed keratin, estrogen receptor, gonadotropin receptors, BRCA1, and originated from monoclonal populations. There was no apparent association between the malignant phenotype and the expression of either matrix metalloproteinases or tissue inhibitors of metalloproteinases. However, a correlation was seen between this phenotype and expression of urokinase (uPA) and tissue type (tPA) plasminogen activators (P = 0.08 and 0.02 respectively).
CONCLUSIONS: The above cell strains provide a useful model for investigating various aspects of the biology of benign ovarian tumors, including their response to steroid and gonadotropin hormones, and the role of specific proteinases in the acquisition of invasive and metastatic abilities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9441775     DOI: 10.1006/gyno.1997.4880

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

2.  Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.

Authors:  Vanessa M Yu; Christine M Marion; Theresa M Austria; Jennifer Yeh; Axel H Schönthal; Louis Dubeau
Journal:  Int J Cancer       Date:  2011-08-29       Impact factor: 7.396

3.  Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.

Authors:  Theresa Austria; Christine Marion; Vanessa Yu; Martin Widschwendter; David R Hinton; Louis Dubeau
Journal:  Int J Cancer       Date:  2018-10-03       Impact factor: 7.396

4.  Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.

Authors:  Louis Dubeau
Journal:  Transl Cancer Res       Date:  2015-02       Impact factor: 1.241

Review 5.  Coming into focus: the nonovarian origins of ovarian cancer.

Authors:  L Dubeau; R Drapkin
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976

6.  Loss of BRCA1-A complex function in RAP80 null tumor cells.

Authors:  Chunjing Bian; Rong Wu; Kathleen Cho; Xiaochun Yu
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

7.  Increased chromosomal stability in cultures of ovarian tumours of low malignant potential compared to cystadenomas.

Authors:  J Yu; D Roy; A D Brockmeyer; L Dubeau
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.